Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Epidermal growth factor (EGF) is a naturally occurring protein that binds to the epidermal growth factor receptor (EGFR), a transmembrane tyrosine kinase receptor. EGF stimulates cell proliferation, differentiation, and survival by activating EGFR-mediated signaling pathways such as MAPK, Akt, and JNK. The binding of EGF to EGFR leads to receptor dimerization and autophosphorylation of intracellular tyrosine residues, triggering downstream signal transduction cascades involved in DNA synthesis and cell proliferation. While not itself a pharmaceutical drug, recombinant forms of EGF have been explored for wound healing and tissue regeneration due to their ability to promote epithelial cell growth[6]. Overactivation or dysregulation of the EGFR pathway is implicated in various cancers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on epidermal growth factor.